All In Biotech

Drug Trial Radar · NCT02983578

Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

Phase II Clinical Trial Evaluating Intravenous AZD9150 (Antisense STAT3) With MEDI4736 (Anti-PD-L1) in Patients With Advanced Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: May 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

39

Actual

Start

Mar 2, 2017

Primary completion

Aug 30, 2025

Study completion Aug 30, 2025

Sponsor

Lead sponsor
M.D. Anderson Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI); AstraZeneca
First posted
Dec 6, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies how well danvatirsen and durvalumab work in treating patients with pancreatic cancer, non-small cell lung cancer and mismatch repair deficient colorectal cancer that has spread to other places in the body and does not respond to treatment. Danvatirsen may be used to block the production of proteins needed for tumor cell growth. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving danvatirsen and durvalumab may work better at treating pancreatic cancer, non-small cell lung cancer and mismatch repair deficient colorectal cancer.

Conditions

  • Advanced Colorectal Carcinoma
  • Advanced Lung Non-Small Cell Carcinoma
  • Lung Non-Small Cell Carcinoma
  • Mismatch Repair Deficiency
  • Refractory Colorectal Carcinoma
  • Refractory Lung Carcinoma
  • Refractory Pancreatic Carcinoma
  • Stage II Pancreatic Cancer AJCC v8
  • Stage III Colorectal Cancer AJCC v8
  • Stage III Lung Cancer AJCC v8
  • Stage III Pancreatic Cancer AJCC v8
  • Stage IIIA Colorectal Cancer AJCC v8
  • Stage IIIA Lung Cancer AJCC v8
  • Stage IIIB Colorectal Cancer AJCC v8
  • Stage IIIB Lung Cancer AJCC v8
  • Stage IIIC Colorectal Cancer AJCC v8
  • Stage IIIC Lung Cancer AJCC v8
  • Stage IV Colorectal Cancer AJCC v8
  • Stage IV Lung Cancer AJCC v8
  • Stage IV Pancreatic Cancer AJCC v8
  • Stage IVA Colorectal Cancer AJCC v8
  • Stage IVA Lung Cancer AJCC v8
  • Stage IVB Colorectal Cancer AJCC v8
  • Stage IVB Lung Cancer AJCC v8
  • Stage IVC Colorectal Cancer AJCC v8

Interventions

  • DanvatirsenDrug

    Given IV

  • DurvalumabBiological

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs), serious AEsTime frame: Up to 4 years
  2. Physiological parameters (Laboratory evaluations)Time frame: Up to 4 years
  3. Incidence of treatment-emergent AEs (TEAEs), SAEs and death(s)Time frame: Up to 4 years
  4. PD-L1 expressionTime frame: Up to 4 years
  5. Phosphorylated or total STAT3 expression levelsTime frame: Up to 4 years
  6. Characterization of immune infiltratesTime frame: Up to 4 years
  7. Quantification and characterization of CD8 staining patternTime frame: Up to 4 years
  8. PD-L1 protein levels in the membrane of circulating tumor cellsTime frame: Baseline up to 4 years
  9. Physiological parametersTime frame: Up to 4 years
  10. Physical ExaminationsTime frame: Up to 4 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • M D Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.